Team

 After a Ph D. in immunoanalysis and glycobiology obtained in 1996, he spend nine years as head of laboratory then scientific and technical director in a subsidiary of Stago group. During this time, L. Landemarre launch a new customized antibodies services department and lead R and D projects for diagnostic (kits, antibodies, reagents) and vaccination (veterinary field) purposes. With his skills for management (laboratory and projects) and specific experience in the fields of biochemistry, immunoanalysis and glycoanalysis, L Landemarre founded GLYcoDiag in august 2005.

Project leader          Perrine Cancellieri, MSc

Ms Cancellieri has joined GLYcoDiag in 2007. Mission: Development of cells assays (microbiology and eucaryotic cells) intended to study glycans-proteins interactions. Objectives: Glycomimetic drug discovery. Identification of stage or species specific glycans expression (cells and tissues).

Scientific Consultant          Eric Duverger, Ph.D.

Ph.D. from University of Orléans in 1995. During this work, he evidenced a new glycodependent nuclear import pathway wich could involved nucleocytosolic lectins. Since 1997, he is assistant professor in cell biology and biochemistry at the University of Orléans. His research area include plant lectin isolation, lignan biosynthesis and nuclear import of plasmids mediated by karyophilic sugars. Since 2009, he has joined the Neurobiology lab (Université d'Orléans) and develops both glycochemistry and glycobiology in collaboration with GLYcoDiag.

Scientific Consultant          Prof. Michel Monsigny

International leader in Glycobiology, M. Monsigny is Professor (emeritus) of Biochemistry/Glycobiology at the University of Orléans, France. M. Monsigny is author (or co-author) of over 200 papers and of 20 patents. Prof. Monsigny was head of the "glycoconjugates and endogenous lectins" department, Centre de Biophysique Moléculaire, CNRS. His research topics include neoglycoprotein and glycosynthon synthesis, plant lectins, endogenous animal lectins, intracellular glycoconjugate trafficking, and sugar-mediated gene therapy.